Filing Flows › Health Care › Ionetix
Ionetix earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026
Q2 2026 Revenue up 9% year over year to $1.2M · operating margin -360.9%
Ionetix made $1.2M in Q2 2026 (+9% Y/Y): Diagnostic drug and medical radioisotopes sales $1.1M, Consulting services and system support services $32K, Cyclotron system sales $14K. Operating margin -360.9%, net loss $15.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.2M in Q2 2026, up 9% year over year and up 10% from the previous quarter. Diagnostic drug and medical radioisotopes sales was the largest line at 96% of revenue. Diagnostic drug and medical radioisotopes sales added $64K year over year (up 6%), 65% of the total change.
Operating costs exceeded revenue by $4.3M, an operating margin of -360.9%. Total costs grew 7% against revenue growth of 9%. The fastest-growing cost line was Cost of revenue (+33%). The quarter ended with a net loss of $15.3M, wider than the previous quarter's $6.9M loss. Net interest and other expense of $11.0M was the main reason.
Operating cash flow was −$7.3M. Non-cash charges added back $855K of depreciation and amortization and $151K of share-based compensation. Working capital and other items added $7.0M. Capital expenditures of $3.5M exceeded it, leaving free cash flow of −$10.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $1.2M | +9% | -360.9% | −$15.3M | −$7.3M |
| Q1 2026 | 10-Q | May 20, 2026 | $1.1M | -59% | -376.5% | −$6.9M | −$2.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Ionetix
Ionetix Corporation (the “Company” or “Ionetix”) is a cyclotron technology platform company providing full-service radioisotope production and end-to-end radiopharmaceutical manufacturing solutions. With its proprietary compact superconducting cyclotron technology, the Company manufactures short-lived diagnostic radioisotopes used in positron emission tomography imaging. The Company also manufactures therapeutic radioisotopes for targeted alpha therapy (“TAT”), an emerging cancer therapy utilizing alpha radionuclides. TAT delivers high-energy alpha particles to cancer cells and the tumor microenvironment to treat cancer while preserving healthy tissue. Ionetix was incorporated in the state of Delaware on December 28, 2009 , and maintains its principal office in Lansing, Michigan.
In its own words, from its 10-Q, filed Aug 12, 2026.
Ionetix against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +9% against the peers' median +6%. Operating margin: -360.9% against the peers' median -1.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| Ionetix | Q2 2026 | $1.2M | +9% | -360.9% |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
Source: Ionetix 10-Q on SEC EDGAR · CIK 2108121 · In Vitro & In Vivo Diagnostic Substances